NCT04994769已完成不适用
The Effect of Extended Use of the Epitomee Capsule on Body Weight in Subjects With Overweight and Obesity With and Without Prediabetes
Epitomee medical6 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2021年8月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 试验地点
- 6
- 主要终点
- Incidence, causality, and severity of serious adverse events, potentially related to Epitomee capsule
研究概览
简要总结
The Effect of Extended Use of the Epitomee Capsule on BodyWeight in subjects with Overweight and Obesity with and without Prediabetes
详细描述
This is an interventional, open label, single arm extension study to assess the long-term safety and efficacy of the Epitomee Capsule in subjects who completed a 24-week treatment period with the Epitomee-Capsule and experienced at least 3% weight loss during that period. All participating subjects will receive the Epitomee capsule arm in combination with lifestyle intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signing an informed consent form prior to any study activity
- •Completed 24 weeks of the core study with maximum of two unattended visits
- •Had at least 3% weight loss in week 24 visit of the core study
- •Non-pregnant, evidenced by a negative urine dipstick pregnancy test by visit 24 week of the core study
- •Females will be either surgically sterile or postmenopausal or agree to continue using an accepted method of birth control during the study
- •Subjects with prediabetes could be untreated or treated with a stable dose of metformin up to 2000 mg/dL inclusive, for at least 1 month prior to entry into the study
- •Currently not using and willingness to avoid non-steroidal anti-inflammatory drugs (NSAIDs) including Diclofenac, Ibuprofen, Naproxen excluding the use of low dose aspirin (75-100 mg) or Celebrex 200-400 mg.
- •Able and willing to continue the lifestyle intervention program as required in the core study including diet and physical activity
- •Subjects must have a primary care physician (PCP) who is responsible for providing routine care
- •Subjects must have cellphone and internet service to communicate with study staff
- •Study subjects must be willing to notify the staff of any change in their medical health (including surgeries) or change in drug treatments (addition of drugs, stopping of drugs, or change in drug dose) during the course of the study
- •Subjects must be willing to avoid medications or other substances known to affect weight changes during the study
- •Subjects on psychiatric medications are clinically well-controlled with a stable psychiatric medication dose for 3 months prior to entry into the extension study
排除标准
- •Currently receiving chronic steroid or immunosuppressive therapy
- •Intending to undergo gastric surgery or gastric banding during the study period.
- •Currently suffering from structural or functional disorders of the esophagus that may impede passage of the device through the gastrointestinal tract, including: Barrett's esophagus, esophagus motility disorder, esophagitis, dysphagia, achalasia, stricture/stenosis, esophageal varices, esophageal diverticula, esophageal perforation, esophageal motility disorder, esophageal chest pain disorders or any other disorder of the esophagus
- •Currently suffering from swallowing disorder, or drug refractory esophageal reflux symptoms
- •Currently suffering from structural or functional disorders of the stomach including, gastric ulcer, chronic gastritis, gastric varices, hiatal hernia (> 2 cm), cancer or any other disorder of the stomach or any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety.
- •Currently suffering from duodenal ulcer, small bowel diverticula (diverticulitis), intestinal varices, intestinal stricture/stenosis, small bowel obstruction, or any other obstructive disorder of the gastrointestinal (GI) tract
- •Currently having ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting
- •Currently having irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease
- •Subjects with Fasting Plasma Glucose ≥126 mg/dL or HbA1c ≥ 6.5% based on blood test results at 24 week visit of the core study
- •Any medications known to be gastric irritants for 4 weeks prior to study start
- •Subjects with congestive heart failure (New York Heart Association (NYHA) Class II, III or IV; myocardial infarction (MI) and/or revascularization (e.g. coronary bypass graft/stent) within 12 months of study start
- •Currently having poorly controlled hypertension (≥ 160 mmHg systolic or ≥ 100 mmHg diastolic)
- •Subjects for whom any anti-platelet drugs beside low dose of Aspirin, have been initiated within 6 months prior to study start
- •Subjects for whom any medications for hypertension or hyperlipidemia have been initiated within 1 month prior to study start
- •Subjects for whom any anti-seizure or anti-arrhythmic medications have been initiated within 6 months prior to study start
- •Subjects who are habitual laxative users or using prescription medication for chronic constipation
- •Any other condition that, in the opinion of the investigator, would interfere with subject participation, may confound the study results, or interfere with compliance with the study (e.g., psychosocial issues, renal disease, hepatic disease, pulmonary disease or cancer disease).
- •Subjects presenting poor abilities and inconsistencies in using the study app during the core study.
结局指标
主要结局
Incidence, causality, and severity of serious adverse events, potentially related to Epitomee capsule
时间窗: 24 weeks
Incidence, causality, and severity of serious adverse events, potentially related to Epitomee capsule during the course of the study
Change in percent weight loss
时间窗: 24 weeks
Change in percent weight loss between baseline weight of the Epitomee core study and week 24 of the extension study
次要结局
- Proportion of subjects who maintain loss of 3% or more of their body weight(24 weeks)
- Change in plasma fasting glucose(24 weeks)
- Overall incidence, causality and severity of adverse events, potentially related to Epitomee capsule.(24 weeks)
- Proportion of subjects who lose or maintain loss of 5 % or more of their body weight(24 weeks)
- Change in glycemic status (Normoglycemia, Prediabetes and Diabetes)(24 weeks)
- Changes in BMI reduction(24 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and ObesityOverweight and ObesityNCT04222322Epitomee medical279
已完成
不适用
Effects of Palatinose™ on Weight Management and Body CompositionOverweight and ObesityDiet ModificationBody WeightNCT03652207Beneo-Institute64
已完成
4 期
Oral Contraceptives and Body Mass IndexBody WeightContraceptive UsageNCT01170390Oregon Health and Science University32
已完成
不适用
Efficacy of Abdominal Catgut Embedding Combined With Auricular Acupressure Therapy for Obese PatientsAcupunctureNCT06133205China Medical University Hospital44
已完成
不适用
Short-Term Follow-up Indicator for Total Knee Arthroplasty and Body Mass IndexTotal Knee ArthroplastyBody Mass IndexRehabilitationNCT02983929Centre Hospitalier Durécu Lavoisier244